Cargando…
Advances in epidermal growth factor receptor specific immunotherapy: lessons to be learned from armed antibodies
The epidermal growth factor receptor (EGFR) has been recognized as an important therapeutic target in oncology. It is commonly overexpressed in a variety of solid tumors and is critically involved in cell survival, proliferation, metastasis, and angiogenesis. This multi-dimensional role of EGFR in t...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7517958/ https://www.ncbi.nlm.nih.gov/pubmed/33014289 http://dx.doi.org/10.18632/oncotarget.27730 |
_version_ | 1783587317986885632 |
---|---|
author | Biteghe, Fleury Augustin Nsole Mungra, Neelakshi Chalomie, Nyangone Ekome Toung Ndong, Jean De La Croix Engohang-Ndong, Jean Vignaux, Guillaume Padayachee, Eden Naran, Krupa Barth, Stefan |
author_facet | Biteghe, Fleury Augustin Nsole Mungra, Neelakshi Chalomie, Nyangone Ekome Toung Ndong, Jean De La Croix Engohang-Ndong, Jean Vignaux, Guillaume Padayachee, Eden Naran, Krupa Barth, Stefan |
author_sort | Biteghe, Fleury Augustin Nsole |
collection | PubMed |
description | The epidermal growth factor receptor (EGFR) has been recognized as an important therapeutic target in oncology. It is commonly overexpressed in a variety of solid tumors and is critically involved in cell survival, proliferation, metastasis, and angiogenesis. This multi-dimensional role of EGFR in the progression and aggressiveness of cancer, has evolved from conventional to more targeted therapeutic approaches. With the advent of hybridoma technology and phage display techniques, the first anti-EGFR monoclonal antibodies (mAbs) (Cetuximab and Panitumumab) were developed. Due to major limitations including host immune reactions and poor tumor penetration, these antibodies were modified and used as guiding mechanisms for the specific delivery of readily available chemotherapeutic agents or plants/bacterial toxins, giving rise to antibody-drug conjugates (ADCs) and immunotoxins (ITs), respectively. Continued refinement of ITs led to deimmunization strategies based on depletion of B and T-cell epitopes or substitution of non-human toxins leading to a growing repertoire of human enzymes capable of inducing cell death. Similarly, the modification of classical ADCs has resulted in the first, fully recombinant versions. In this review, we discuss significant advancements in EGFR-targeting immunoconjugates, including ITs and recombinant photoactivable ADCs, which serve as a blueprint for further developments in the evolving domain of cancer immunotherapy. |
format | Online Article Text |
id | pubmed-7517958 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Impact Journals LLC |
record_format | MEDLINE/PubMed |
spelling | pubmed-75179582020-10-01 Advances in epidermal growth factor receptor specific immunotherapy: lessons to be learned from armed antibodies Biteghe, Fleury Augustin Nsole Mungra, Neelakshi Chalomie, Nyangone Ekome Toung Ndong, Jean De La Croix Engohang-Ndong, Jean Vignaux, Guillaume Padayachee, Eden Naran, Krupa Barth, Stefan Oncotarget Review The epidermal growth factor receptor (EGFR) has been recognized as an important therapeutic target in oncology. It is commonly overexpressed in a variety of solid tumors and is critically involved in cell survival, proliferation, metastasis, and angiogenesis. This multi-dimensional role of EGFR in the progression and aggressiveness of cancer, has evolved from conventional to more targeted therapeutic approaches. With the advent of hybridoma technology and phage display techniques, the first anti-EGFR monoclonal antibodies (mAbs) (Cetuximab and Panitumumab) were developed. Due to major limitations including host immune reactions and poor tumor penetration, these antibodies were modified and used as guiding mechanisms for the specific delivery of readily available chemotherapeutic agents or plants/bacterial toxins, giving rise to antibody-drug conjugates (ADCs) and immunotoxins (ITs), respectively. Continued refinement of ITs led to deimmunization strategies based on depletion of B and T-cell epitopes or substitution of non-human toxins leading to a growing repertoire of human enzymes capable of inducing cell death. Similarly, the modification of classical ADCs has resulted in the first, fully recombinant versions. In this review, we discuss significant advancements in EGFR-targeting immunoconjugates, including ITs and recombinant photoactivable ADCs, which serve as a blueprint for further developments in the evolving domain of cancer immunotherapy. Impact Journals LLC 2020-09-22 /pmc/articles/PMC7517958/ /pubmed/33014289 http://dx.doi.org/10.18632/oncotarget.27730 Text en https://creativecommons.org/licenses/by/3.0/ Copyright: © 2020 Biteghe et al. This is an open access article distributed under the terms of the Creative Commons Attribution License (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. |
spellingShingle | Review Biteghe, Fleury Augustin Nsole Mungra, Neelakshi Chalomie, Nyangone Ekome Toung Ndong, Jean De La Croix Engohang-Ndong, Jean Vignaux, Guillaume Padayachee, Eden Naran, Krupa Barth, Stefan Advances in epidermal growth factor receptor specific immunotherapy: lessons to be learned from armed antibodies |
title | Advances in epidermal growth factor receptor specific immunotherapy: lessons to be learned from armed antibodies |
title_full | Advances in epidermal growth factor receptor specific immunotherapy: lessons to be learned from armed antibodies |
title_fullStr | Advances in epidermal growth factor receptor specific immunotherapy: lessons to be learned from armed antibodies |
title_full_unstemmed | Advances in epidermal growth factor receptor specific immunotherapy: lessons to be learned from armed antibodies |
title_short | Advances in epidermal growth factor receptor specific immunotherapy: lessons to be learned from armed antibodies |
title_sort | advances in epidermal growth factor receptor specific immunotherapy: lessons to be learned from armed antibodies |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7517958/ https://www.ncbi.nlm.nih.gov/pubmed/33014289 http://dx.doi.org/10.18632/oncotarget.27730 |
work_keys_str_mv | AT biteghefleuryaugustinnsole advancesinepidermalgrowthfactorreceptorspecificimmunotherapylessonstobelearnedfromarmedantibodies AT mungraneelakshi advancesinepidermalgrowthfactorreceptorspecificimmunotherapylessonstobelearnedfromarmedantibodies AT chalomienyangoneekometoung advancesinepidermalgrowthfactorreceptorspecificimmunotherapylessonstobelearnedfromarmedantibodies AT ndongjeandelacroix advancesinepidermalgrowthfactorreceptorspecificimmunotherapylessonstobelearnedfromarmedantibodies AT engohangndongjean advancesinepidermalgrowthfactorreceptorspecificimmunotherapylessonstobelearnedfromarmedantibodies AT vignauxguillaume advancesinepidermalgrowthfactorreceptorspecificimmunotherapylessonstobelearnedfromarmedantibodies AT padayacheeeden advancesinepidermalgrowthfactorreceptorspecificimmunotherapylessonstobelearnedfromarmedantibodies AT narankrupa advancesinepidermalgrowthfactorreceptorspecificimmunotherapylessonstobelearnedfromarmedantibodies AT barthstefan advancesinepidermalgrowthfactorreceptorspecificimmunotherapylessonstobelearnedfromarmedantibodies |